(NASDAQ: KYTX) Kyverna Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 84.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Kyverna Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast KYTX's revenue for 2027 to be $1,607,441,442, with the lowest KYTX revenue forecast at $185,956,368, and the highest KYTX revenue forecast at $3,028,926,517. On average, 1 Wall Street analysts forecast KYTX's revenue for 2028 to be $1,712,528,413, with the lowest KYTX revenue forecast at $1,712,528,413, and the highest KYTX revenue forecast at $1,712,528,413.
In 2029, KYTX is forecast to generate $6,828,490,819 in revenue, with the lowest revenue forecast at $6,828,490,819 and the highest revenue forecast at $6,828,490,819.